Safety and efficacy of nimotuzumab combined with chemoradiotherapy in Chinese patients with locally advanced cervical cancer

Figures & data

Table 1 Patients’ characteristics

Variables	Number of patients, N=80 (%)
Age (years)
Median (minimum–maximum)	59 (24–78)
Pathological diagnosis
Squamous cell carcinoma	48 (60)
Adenocarcinoma	22 (28)
Adenosquamous	10 (12)
Eastern Cooperative Oncology Group performance status at baseline
1	65 (81)
2	15 (19)
Staging of cervical cancer based on Federation of Gynecology and Obstetrics
IIB	17 (21)
III	38 (48)
IVA	25 (31)

Figure 1 Kaplan–Meier curve of PFS (enrolled population).

Abbreviations: CI, confidence interval; PFS, progression-free survival.

Figure 2 Kaplan–Meier curve of OS (enrolled population).

Abbreviations: CI, confidence interval; OS, overall survival.

Table 2 Summary of tumor response (tumor-response qualified population)

Variables	Number of patients, N=80 (%)
Complete response (CR)	0
Partial response (PR)	11 (14)
Tumor response rate (CR + PR)	11 (14)
Stable disease (SD)	59 (74)
Disease control rate (CR + PR + SD)	70 (88)
Progressive disease (PD)	10 (13)

Table 3 Summary of treatment-related adverse events experienced in women with locally advanced cervical cancer after nimotuzumab plus chemoradiotherapy

Adverse events	Grade 1, n (%)	Grade 2, n (%)	Grade 3, n (%)	Grade 4, n (%)	All grades, n (%)
Mucositis	20 (25)	17 (21)	8 (10)	0 (0)	45 (56)
Gastrointestinal disturbance	18 (23)	8 (10)	2 (3)	0 (0)	28 (35)
Leukocytopenia	19 (24)	15 (19)	3 (4)	0 (0)	37 (46)
Anemia	17 (21)	7 (9)	3 (4)	0 (0)	27 (34)
Thrombocytopenia	18 (23)	13 (16)	4 (5)	0 (0)	35 (44)
Granulocytopenia	14 (18)	8 (10)	0 (0)	0 (0)	22 (28)
Febrile neutropenia	11 (14)	9 (11)	0 (0)	0 (0)	20 (25)
Fatigue	8 (10)	4 (5)	0 (0)	0 (0)	12 (15)
Nausea/vomiting	7 (9)	8 (10)	0 (0)	0 (0)	15 (19)
Radiodermatitis	8 (10)	6 (8)	1 (1)	0 (0)	15 (19)
Rash	7 (9)	6 (8)	0 (0)	0 (0)	13 (16)
Anorexia	8 (10)	5 (6)	0 (0)	0 (0)	13 (16)
Proctitis	6 (8)	4 (5)	0 (0)	0 (0)	10 (13)
Fever	7 (9)	0 (0)	0 (0)	0 (0)	7 (9)
Pain	9 (11)	2 (3)	0 (0)	0 (0)	11 (14)
Weight loss	8 (10)	5 (6)	0 (0)	0 (0)	13 (16)

Note: Grade 1 indicates minimal effect, grade 2 indicates mild effect, grade 3 indicates moderate effect, and grade 4 indicates severe effect.